Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Rooney

Showing results (161-170 of 165) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 165 results.
The Lancet. HIV|November 12, 2023
Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trialRaphael J Landovitz, Brett S Hanscom, Meredith E Clement, et al.
Lancet (London, England)|April 4, 2022
Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trialSinead Delany-Moretlwe, James P Hughes, Peter Bock, et al.
The New England Journal of Medicine|November 25, 2010
Preexposure chemoprophylaxis for HIV prevention in men who have sex with menRobert M Grant, Javier R Lama, Peter L Anderson, et al.
The New England Journal of Medicine|July 18, 2019
HIV Testing and Treatment with the Use of a Community Health Approach in Rural AfricaDiane V Havlir, Laura B Balzer, Edwin D Charlebois, et al.
The New England Journal of Medicine|August 11, 2021
Cabotegravir for HIV Prevention in Cisgender Men and Transgender WomenRaphael J Landovitz, Deborah Donnell, Meredith E Clement, et al.
Pageof 17

Showing results (161-170 of 165) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 165 results.
The Lancet. HIV|November 12, 2023
Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trialRaphael J Landovitz, Brett S Hanscom, Meredith E Clement, et al.
Lancet (London, England)|April 4, 2022
Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trialSinead Delany-Moretlwe, James P Hughes, Peter Bock, et al.
The New England Journal of Medicine|November 25, 2010
Preexposure chemoprophylaxis for HIV prevention in men who have sex with menRobert M Grant, Javier R Lama, Peter L Anderson, et al.
The New England Journal of Medicine|July 18, 2019
HIV Testing and Treatment with the Use of a Community Health Approach in Rural AfricaDiane V Havlir, Laura B Balzer, Edwin D Charlebois, et al.
The New England Journal of Medicine|August 11, 2021
Cabotegravir for HIV Prevention in Cisgender Men and Transgender WomenRaphael J Landovitz, Deborah Donnell, Meredith E Clement, et al.
Pageof 17